Masimo Corporation

706 articles about Masimo Corporation

• Masimo Announces FDA 510(k) Clearance of Radius VSM™

  6/5/2023

  Masimo (NASDAQ: MASI) today announced that Radius VSM™ , a patient-worn, continuous multi-parameter vital signs monitor, has received FDA 510(k) clearance.

• Masimo to Present in Jefferies 2023 Healthcare Conference

  6/5/2023

  Masimo announced that its management will participate in the Jefferies Healthcare Conference on Thursday, June 8, 2023 at 11:00 a.m. Eastern Time.

• CORRECTING and REPLACING Masimo Board of Directors Authorizes Appointment of Michelle Brennan as Sixth Director Pending Stockholder Approval of Board Expansion and Election of Company Nominees

  6/2/2023

  The Board of Directors of Masimo Corporation announced its commitment to appoint Michelle Brennan as the Company’s sixth director, pending stockholder approval of the proposal to expand the Board of Directors to seven and the election of the Company’s highly qualified director nominees, H Michael Cohen and Julie Shimer, Ph.D. Ms. Brennan was nominated by Politan Capital Management.

• Masimo Board of Directors Authorizes Appointment of Michelle Brennan as Sixth Director Pending Stockholder Approval of Board Expansion and Election of Company Nominees

  6/2/2023

  The Board of Directors of Masimo Corporation announced its commitment to appoint Michelle Brennan as the Company’s sixth director, pending stockholder approval of the proposal to expand the Board of Directors to seven and the election of the Company’s highly qualified director nominees, H Michael Cohen and Julie Shimer, Ph.D.

• Masimo Files Investor Presentation Highlighting Track Record of Success, Compelling Strategy, Responsive Governance Changes and Risks Posed by Quentin Koffey’s Agenda

  5/31/2023

  Masimo Corporation filed an investor presentation with the U.S. Securities and Exchange Commission in connection with its Annual Meeting of Stockholders to be held on June 26, 2023.

• Masimo Board of Directors Files Definitive Proxy and Issues Letter to Stockholders

  5/26/2023

  The Masimo Corporation Board of Directors issued a letter to stockholders in connection with its definitive proxy materials filed on May 24, 2023, and the Company’s Annual Meeting of Stockholders to be held on June 26, 2023.

• Masimo Announces Major Expansion of the HEOS® Platform

  5/24/2023

  Masimo announced the global expansion of the HEOS platform, enabling an always-on connection to the Masimo Health secure cloud for four million devices and empowering consumers with an enhanced health tracking experience.

• Masimo Reports First Quarter 2023 Financial Results

  5/9/2023

  Masimo announced its financial results for the first quarter of 2023, ended April 1, 2023.

• Cambridge University Hospitals Expands Virtual Care Program with Masimo W1™

  5/8/2023

  Masimo announced that Cambridge University Hospitals NHS Foundation Trust, U.K. is adopting the Masimo W1™ advanced health tracking watch for use in its telehealth and telemedicine programs.

• Masimo to Report First Quarter 2023 Financial Results After Market Close on Tuesday, May 9

  4/25/2023

  Masimo (NASDAQ: MASI) will release first quarter 2023 financial results for the period ended April 1, 2023, after the market closes on Tuesday, May 9, 2023.

• Masimo Announces FDA Clearance of the Rad-G® with Temperature

  4/18/2023

  Masimo (NASDAQ: MASI) today announced that the Rad-G ® with Temperature has received FDA 510(k) clearance.

• Masimo Opioid Halo™ Granted De Novo for the First and Only FDA-Authorized Opioid Overdose Prevention and Alert System

  4/3/2023

  Masimo (NASDAQ: MASI) today announced that Masimo Opioid Halo™, an opioid overdose prevention and alert system, has been granted a De Novo by the FDA – making it the first and only FDA-cleared monitoring solution for detecting opioid-induced respiratory depression, the leading cause of death from opioid overdose.

• Masimo Announces Changes to Governance Structure and Practices

  3/23/2023

  Masimo Corporation announced changes to its Board of Directors and governance policies, the result of an ongoing board refreshment and governance review process informed by regular engagement with stockholders.

• New Study Finds That Masimo PVi® Reliably Predicted Fluid Responsiveness in Young Children Undergoing Neurosurgery

  3/9/2023

  Masimo announced the findings of a prospective study published in Pediatrics International in which Dr. Ya-Fei Liu and colleagues at Peking University First Hospital in Beijing evaluated the ability of noninvasive, continuous Masimo PVi®, alongside other dynamic parameters, to predict fluid responsiveness in children 1-3 years old who were undergoing major neurosurgery.

• Masimo and Temple Health Form Innovation Collaboration with Focus on Hospital Automation and Telehealth Initiatives

  3/7/2023

  Masimo, a leading global provider of medical technology and automation solutions, and Temple Health, Philadelphia’s 979-bed academic health system, announced that they are entering into a strategic innovation collaboration.

• New Study Evaluates the Use of Masimo PVi® As an Indicator of Fluid Responsiveness to Guide Goal-Directed Fluid Therapy in Adult Neurosurgical Patients

  3/6/2023

  Masimo (NASDAQ: MASI) today announced the findings of a prospective study published in the British Journal of Neurosurgery in which Dr. Ankita Dey and colleagues at institutions in Bathinda and Pondicherry, India evaluated the use of noninvasive, continuous Masimo PVi®.

• Masimo to Present in 44th Annual Raymond James Institutional Investors Conference

  3/2/2023

  Masimo (NASDAQ: MASI) today announced that its management will participate in the 44th Annual Raymond James Institutional Investors on Tuesday, March 7, 2023 at 11:00 a.m. Eastern Time.

• Masimo Reports Fourth Quarter and Full-Year 2022 Financial Results

  2/28/2023

  Masimo (Nasdaq: MASI) today announced its financial results for the fourth quarter and full-year ended December 31, 2022.

• New Study Evaluates the Utility of Masimo ORi™ in Reducing Hyperoxemia During Laparoscopic Gastrectomy

  2/21/2023

  Masimo announced the findings of a prospective, double-blinded, randomized controlled study published in Medicine in which Dr. Jin Hee Ahn and colleagues at the Sungkyunkwan University School of Medicine in Seoul, Korea, evaluated the ability of Masimo ORi™ to assist clinicians in guiding supplemental oxygenation during elective laparoscopic gastrectomy surgery.

• Masimo to Report Fourth Quarter and FY 2022 Financial Results After Market Close on Tuesday, February 28

  2/14/2023

  Masimo (NASDAQ: MASI) will release fourth quarter and FY 2022 financial results for the period ended December 31, 2022, after the market closes on Tuesday, February 28, 2023.